Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
191. |
ECCT/19/03/03 | Biofire FilmArray Gobal Fever GF Panel Clinical Evaluation of the FilmArray Gobal Fever GF Panel |
Principal Investigator(s) 1. JOHN WAITUMBI Site(s) in Kenya KEMRI Walter Reed Project USAMRD A/K Kisumu |
16-05-2019 |
View |
192. |
ECCT/18/11/01 | PrIMA PrEP Implementation for Mothers in Antenatal Care |
Principal Investigator(s) 1. Grace John-Stewart John-Stewart 2. Jared Baeten Site(s) in Kenya 1. Homa Bay County - 10 sites (Homa Bay county) 2. Siaya County - 10 sites (Siaya county) |
16-05-2019 |
View |
193. |
ECCT/19/03/05 | EPI-MAL-003 (Siaya) A prospective study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa (v1.0 11Oct2017): Site-specific protocol for Siaya County, western Kenya |
Principal Investigator(s) 1. Simon Kariuki 2. Martina Oneko Site(s) in Kenya 1. Bondo sub-county (Siaya county) 2. Gem sub-county (Siaya county) |
17-05-2019 |
View |
194. |
ECCT/19/03/02 | PREVENT TD A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg daily or 550 mg twice daily) for Chemoprophylaxis Against Travellers’ Diarrhoea (TD) Among Active Duty Deployed U.S. and British Military Personnel (PREVENT TD) |
Principal Investigator(s) 1. Flynn Alexander Site(s) in Kenya Nyati Barracks, British Army Training Unit, Kenya |
10-06-2019 |
View |
195. |
ECCT/19/06/01 | EPI 003 A prospective study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa. |
Principal Investigator(s) 1. Walter Otieno Site(s) in Kenya 1. Ahero clinical triasl unit (Kisumu county) 2. KEMI CDC (Siaya county) |
17-06-2019 |
View |
196. |
ECCT/19/04/03 | Phase III pediatric study with the L-PZQ ODTs An Open-label, Phase 3 efficacy and safety study of L-praziquantel orodispersible tablets (L-PZQ ODT) in Schistosoma-infected children 3 months to 6 years of age, including a 2:1 randomized, controlled cohort of Schistosoma mansoni-infected children 4 to 6 years of age treated with L-PZQ ODT or commercial PZQ (Biltricide®) |
Principal Investigator(s) 1. Maurice Reuben Odiere Site(s) in Kenya KEMRI-Centre for Global Health Research (CGHR) |
18-06-2019 |
View |
197. |
ECCT/19/05/02 | ETNA EVALUATION OF TECHNOLOGIES FOR NEONATES IN AFRICA |
Principal Investigator(s) 1. PROF WILLIAM MAINA MACHARIA Site(s) in Kenya 1. AGA KHAN UNIVERSITY HOSPITAL (Nairobi City county) 2. PUMWANI MATERNITY HOSPITAL (Nairobi City county) |
18-06-2019 |
View |
198. |
ECCT/19/03/04 | NIFTY Non-Inferiority Fractional-Doses Trial For Yellow Fever Vaccine |
Principal Investigator(s) 1. George Warimwe Site(s) in Kenya KEMRI Kilifi |
21-06-2019 |
View |
199. |
ECCT/19/04/04 | Effectiveness of an integrated programme to reduce maternal and child malnutrition in Kenya Effectiveness of an integrated programme to reduce maternal and child malnutrition in Kenya:two cluster-randomized controlled trials in pregnant women and their offspring and in 6-59 months old children comparing an agricultural intervention alone with a combined agricultural, nutrition and WASH intervention. |
Principal Investigator(s) 1. Rita Wegmuller Site(s) in Kenya 1. Kakamega and Bungoma (Kakamega county) |
05-07-2019 |
View |
200. |
ECCT/19/04/01 | A study to determine if a new shigella vaccine (Shigella4V) is safe, induces immunity and the best dose among Kenyan infants. Safety and immunogenicity of a Shigella-tetravalent bioconjugate vaccine: A phase 1/2 randomized controlled and age descending study including dose finding in 9-month-old infants |
Principal Investigator(s) 1. Mainga Hamaluba 2. Kosgei Josphat Site(s) in Kenya 1. KEMRI-United States Army Medical Research Unit-Kenya, Kericho (Kericho county) 2. KEMRI Wellcome Trust Research Program-CGMR-C (Kilifi county) |
08-07-2019 |
View |